NCT05870787Completed
iMproving thE DIagnostics And Treatment Of ceRvical Precancer
Source: ClinicalTrials.gov · Last updated 10 Feb 2026
Brief summary (registry, in English)
Cervical cancer screening is important as it enables identification of women at increased risk of the disease, but high-quality diagnostics of screen-positive women and effective treatment of those with precancer are critical in preventing progression to cancer. With the current transition from cytology-based to primary human papillomavirus (HPV)-screening and a growing proportion of HPV-vaccinated women, diagnostics of screen-positive women will become more challenging in the decades to come. Thus, there is a need to explore how to improve diagnostics while ensuring a low number of unnecessary procedures such as colposcopy and the collection of multiple cervical biopsies. The overall purposes are: Purpose 1: To investigate the diagnostic accuracy of cervical precancer when using a colposcopic scoring system in the diagnostic work-up of screen-positive women. Purpose 2: To investigate the performance of a colposcopic scoring system to identify women without cervical precancer in whom collection of biopsies can be safely omitted.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 929 (actual)
- First submitted
- 12 May 2023
- Start date
- 1 Mar 2023
- Primary completion date
- 6 Dec 2024
- Lead sponsor
- University of Aarhus
- Diseases
- Cervical cancer
- NCT number
- NCT05870787
What you commit to
- Study type: Observational
- Participants enrolled: 929
- From 1 Mar 2023 to the primary completion date, 6 Dec 2024
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Women with previous hysterectomy or without a cervix due to cervical cancer will be excluded.
Other illness
- Allergic to iodine.
Other
- Tranformationzone not visible (type 3).
- Atrophy of cervical epithelium.
- Women referred to colposcopy with no cervical biopsies taken or invalid cervical biopsies.
- Pregnant women.
Who the study is looking for
- Women referred to colposcopy due to abnormal smear (HPV-genotype and cytology) in Central Denmark Region or Southern Denmark Region.
Age in the registry: 23 years to 99 years · Sex: Female · Accepts healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guldberg Kvindeklinik Coordinator of this site? Confirm its status | Fredericia | Denmark | Unknown status |
| Gødstrup Regional Hospital Coordinator of this site? Confirm its status | Herning | Denmark | Unknown status |
| Horsens Gynækologisk Klinik Coordinator of this site? Confirm its status | Horsens | Denmark | Unknown status |
| Horsens Regional Hospital Coordinator of this site? Confirm its status | Horsens | Denmark | Unknown status |
| Odense Univeristy Hospital Coordinator of this site? Confirm its status | Odense | Denmark | Unknown status |
| Randers Regional Hospital Coordinator of this site? Confirm its status | Randers | Denmark | Unknown status |
| Viborg Regional Hospital Coordinator of this site? Confirm its status | Viborg | Denmark | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.